TrialJournal of hematology & oncology2021

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.

Heng Mei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.